Submit Manuscript  

Article Details

Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis

[ Vol. 4 , Issue. 4 ]


Richard E. Kast and Cristobal Belda-Iniesta   Pages 314 - 317 ( 4 )


Strong expression of aldehyde dehydrogenase is a prominent feature of both normal and cancer stem cells, including the stem cell sub-population of glioblastoma. Aldehyde dehydrogenase function is used by cancer stem cells to repopulate a tumor mass after chemotherapy cytoreduction. Cancer stem cells that undrgo chemotherapy can be resistant compared to the non-stem cell majority cell population in several common human cancers. Such has been demonstrated specifically in glioblastoma. In normal hematopoietic stem cells with unimpaired high levels of aldehyde dehydrogenase, stem cells divide rarely and then asymmetrically to a daughter stem cell and a daughter cell on a path of differentiation or symmetrically with both daughter cells on a differentiated path. If a parallel situation obtains in glioblastoma stem cells, the migrating, far flung paucicellular extensions become stem cell rich and use aldehyde dehydrogenase to generate the characteristic multiple metastases made up of mostly non-stem cells. With the inhibition of aldehyde dehydrogenase, stem cell division to non-stem daughter cells tends to become blocked. We have three old yet potent aldehyde dehydrogenase inhibitors on the market- chloral hydrate, chloramphenicol, and disulfiram- they should be investigated as adjuncts in glioblastoma chemotherapy. If GBM stem cell function can be thwarted by potent aldehyde dehydrogenase inhibition, they will be less able to regenerate a stem cell derived tumor mass after primary resection or chemotherapy.


Aldehyde dehydrogenase, chloramphenicol, chemotherapy, disulfiram, glioblastoma, tretinoin, stem cells


University of Vermont, 2 Church Street, Burlington, VT 05401 USA; Translational Oncology and Experimental Therapeutics Unit CSIC/UAM at Medical Oncology Division, University Hospital La Paz. School of Medicine, Universidad Autonoma de Madrid, Paseo de la Castellana 261, 28046 Madrid, Spain.

Read Full-Text article